T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.
The medical management of idiopathic inflammatory bowel disease (IBD) has historically been based upon the use of broad-spectrum anti-inflammatory drugs such as corticosteroids and thiopurines. Recently, the identification of novel mechanisms central to the pathophysiology of IBD has provided more specific targets, including inhibition of leukocyte trafficking to the gut. In this article, we discuss the molecular biology of intestinal leukocyte trafficking and review the emerging therapies that target this process, including vedolizumab, natalizumab, etrolizumab, PF-547659, alicaforsen, efalizumab, and emerging members of this class.
Department of Medicine, University of Western Ontario, 100 Perth Dr, London, ON, N6A 5K8, Canada.
Mahmoud H
MH
Mosli
Jesus
J
Rivera-Nieves
Brian G
BG
Feagan
D002448:Cell Adhesion / Q000187:drug effects*; D002465:Cell Movement / Q000187:drug effects*; D054357:Chemokine CXCL10 / Q000037:antagonists & inhibitors; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D039441:Integrin alpha4 / Q000502:physiology; D039641:Integrin beta Chains / Q000502:physiology; D016023:Integrins / Q000037:antagonists & inhibitors; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D049349:Receptors, Lysosphingolipid / Q000819:agonists / Q000502:physiology; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000187:drug effects* / Q000502:physiology
D054357:Chemokine CXCL10; D039641:Integrin beta Chains; D016023:Integrins; D049349:Receptors, Lysosphingolipid; C071777:integrin alpha4beta7; C091368:integrin beta7; D039441:Integrin alpha4